	Monthly Cohort (n = 30)	**TREX Cohort (n = 60)**	**GILA Cohort (n = 60)**
Ocular SAE's, Total, n (%)			
Optic neuropathy	1		
Vitreous hemorrhage		1	1
Non-ocular SAE's, Total, n (%)			
Cardiac disorders			
Acute myocardial infarction	1*	1*	1
Angina pectoris		1	1
Arrhythmia			1
Congestive heart failure			1
Peripheral edema			1
Gastrointestinal disorders			
Cholecystitis	1		
Emesis			1
Hematologic disorders			
Anemia			1
Infectious/Inflammatory disorders			
Respiratory infection	1*	1*	1*
Sepsis		1*	

Metabolism and endocrine disorders			
Hypo/Hyperglycemia	1*	1*	1
Musculoskeletal disorders			
Arthritis			1
Neoplasms, benign, malignant, and unspecified			
Multiple Myeloma/Leukemia			2
Nervous system/Psychiatric disorders			
Cerebral hemorrhage			1
Cerebrovascular accident	1*	1*	
Renal and urinary disorders			
Renal insufficiency/failure		2*	2*
Vascular disorders			
Worsening hypertension		1	

* Serious adverse event occurred in a patient who had both eyes enrolled into the study.

Supplemental Table 2: Serious adverse events (SAE's) over the third year of the study.